

Special Issue

Chronic Pain

Message from the Guest Editor

The Clinical Pharmacogenetics Consortium (CPIC) provided guidelines on stratification of pro-opioids based on CYP2D6 function, suggesting generalized recommendations for poor and ultrarapid metabolizers. Variations in other genes have been implicated in determining response to opioids, including OPRM1, COMT, and ABCC1; however, no clinical guidelines or protocols have been developed. Upcoming CPIC recommendations expand on the role of variations in the CYP2C9 on NSAIDs. Alternative non-opioid treatment options for chronic pain include SNRIs, TCAs, antiepileptics, and cannabinoids, yet clinical protocols for evidence-based management of chronic pain have not been detailed for various types of chronic pain conditions, such as cancer pain, fibromyalgia, arthritis, IBD, and neuropathic pain. The *Journal of Personalized Medicine* is now opening a Special Issue that is fully devoted to evidence-based chronic pain management, with a call for papers involving basic, translational, and clinical research on this topic.


Guest Editor

Dr. Ruslan Dorfman

Department of Anesthesia, McMaster University, Hamilton, ON, Canada

Deadline for manuscript submissions

closed (20 December 2020)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/32852

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).